STOCK TITAN

Institutional Investor Reports 11.32M Shares of 180 Life Sciences (ATNFW)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Steadfast Capital Management LP and affiliated entities reported beneficial ownership of 11,320,754 shares of 180 Life Sciences Corp. common stock, equal to 7.3% of 154,032,084 shares outstanding. The filing names the Investment Manager, American Steadfast, Steadfast International Master Fund and Robert S. Pitts Jr.; Mr. Pitts is the controlling principal of the Investment Manager. The Investment Manager has shared voting and dispositive power over the shares held by the two funds. The statement certifies the holdings are not held to change or influence control of the issuer.

Positive

  • Reported beneficial ownership of 11,320,754 shares, representing 7.3% of outstanding common stock

Negative

  • None.

Insights

TL;DR: A meaningful passive stake disclosed—material but non-control, signaling investor interest without activist intent.

The Reporting Persons disclose an aggregate position of 11,320,754 shares, representing 7.3% of outstanding common stock based on the issuer's reported 154,032,084 shares outstanding. Filing on Schedule 13G and the included certification indicate this is a passive disclosure rather than an active control pursuit. For investors, this signals sizeable institutional interest that could affect liquidity and shareholding dynamics but does not indicate imminent governance changes.

TL;DR: Grouped ownership under a single manager with shared voting power, but the filing affirms no intent to influence control.

The filing identifies a clear reporting group structure: an investment manager, two funds and an individual controlling principal who holds shared voting and dispositive power over the disclosed shares. The certification in Item 10 aligns the filing with passive investor status under Schedule 13G rules. From a governance perspective, the arrangement creates a concentrated but disclosed block that management and other shareholders should monitor for voting alignment, though no change-of-control objective is stated.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



STEADFAST CAPITAL MANAGEMENT LP
Signature:/s/ Sheena Koshy
Name/Title:Sheena Koshy/Chief Operating Officer
Date:08/12/2025
American Steadfast, L.P.
Signature:/s/ Sheena Koshy
Name/Title:Sheena Koshy/Chief Operating Officer of Steadfast Capital Management LP, Attorney-in-Fact
Date:08/12/2025
Steadfast International Master Fund Ltd.
Signature:/s/ Sheena Koshy
Name/Title:Director
Date:08/12/2025
Robert S. Pitts, Jr.
Signature:/s/ Robert S. Pitts, Jr
Name/Title:Robert S. Pitts, Jr.
Date:08/12/2025
Exhibit Information

Exhibit A - Joint Filing Agreement Exhibit B

FAQ

Who filed the Schedule 13G for 180 Life Sciences Corp. (ATNFW)?

Steadfast Capital Management LP, American Steadfast L.P., Steadfast International Master Fund Ltd. and Robert S. Pitts Jr.

How many shares and what percentage did the Reporting Persons disclose for ATNFW?

11,320,754 shares, representing 7.3% of 154,032,084 shares outstanding

Does the Schedule 13G indicate the stake is intended to change control of 180 Life Sciences (ATNFW)?

No; Item 10 includes a certification that the securities were not acquired to change or influence control.

Which entities hold the disclosed shares for ATNFW and how is voting power described?

American Steadfast holds 4,109,434 shares and the Offshore Fund holds 7,211,320 shares; shared voting and dispositive power with the Investment Manager and Mr. Pitts is reported.

Who is identified as the controlling principal of the Investment Manager?

Robert S. Pitts Jr. is identified as the controlling principal of the Investment Manager.
180 Life Sciences Corp

NASDAQ:ATNFW

ATNFW Rankings

ATNFW Latest News

ATNFW Latest SEC Filings

ATNFW Stock Data

5.19M
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO